Standout Papers

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events 2015 2026 2018 2022 1.6k
  1. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events (2015)
    Jennifer G. Robinson, Michel Farnier et al. New England Journal of Medicine
  2. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease (2020)
    Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk et al. New England Journal of Medicine
  3. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk (2019)
    Michelle L. O’Donoghue, Sergio Fazio et al. Circulation
  4. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials (2016)
    Nicholas J. Viney, Julian C. van Capelleveen et al. The Lancet
  5. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans (2016)
    Fleur M. van der Valk, Siroon Bekkering et al. Circulation
  6. Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance (2014)
    Erik S.G. Stroes, David Colquhoun et al. Journal of the American College of Cardiology
  7. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome (2019)
    Joseph L. Witztum, Daniel Gaudet et al. New England Journal of Medicine
  8. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease (2019)
    Anne C. Goldberg, Lawrence A. Leiter et al. JAMA
  9. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance (2019)
    Ulrich Laufs, Maciej Banach et al. Journal of the American Heart Association
  10. Evinacumab in Patients with Refractory Hypercholesterolemia (2020)
    Robert S. Rosenson, Lesley Burgess et al. New England Journal of Medicine
  11. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis (2019)
    Kang H. Zheng, Sotirios Tsimikas et al. Journal of the American College of Cardiology
  12. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels (2022)
    Steven E. Nissen, Kathy Wolski et al. JAMA
  13. Association of Lipoprotein(a) With Atherosclerotic Plaque Progression (2022)
    Yannick Kaiser, Marwa Daghem et al. Journal of the American College of Cardiology

Immediate Impact

3 by Nobel laureates 7 from Science/Nature 89 standout
Sub-graph 1 of 19

Citing Papers

Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
2025 Standout
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
2024 Standout
61 intermediate papers

Works of Erik S.G. Stroes being referenced

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
2019 Standout
Lipoprotein Lipase S447X
2006
and 40 more

Author Peers

Author Last Decade Papers Cites
Erik S.G. Stroes 13344 7919 6575 490 28.5k
Stephen J. Nicholls 16519 8452 8730 663 29.2k
Alberico L. Catapano 14340 7003 8163 628 28.9k
J. Wouter Jukema 16605 12798 6162 881 36.4k
Ulrich Laufs 10282 9368 3601 495 27.4k
Maciej Banach 9616 6751 4852 958 27.6k
Jean‐Claude Tardif 11990 12448 7761 521 28.6k
Ulf Landmesser 10458 14767 4283 558 32.9k
Jacques Genest 15748 12801 10316 704 39.5k
Anne Tybjærg‐Hansen 10644 7161 9027 341 27.4k
Kausik K. Ray 13980 6441 9730 450 25.2k

All Works

Loading papers...

Rankless by CCL
2026